NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Grit Biotherapeutics

Grit Biotherapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://grit-bio.com/

Last Round

Series B

Sep 8, 2023

Total Funding Raised

$75.4M

Company Overview

Grit Biotherapeutics is a biopharmaceutical company that develops tumor-infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

TIL therapycell therapyimmunotherapyoncology biotechsolid tumor treatmentin-vivo CAR-TCAR-Tclinical-stage biotechgene therapypersonalized medicineautologous cell therapyCRISPR gene editingTumor-Infiltrating LymphocyteTIL expansionmRNA deliveryautoimmune disease therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Grit Biotherapeutics Comparables

Compare Grit Biotherapeutics with similar companies based on industry and business-model similarity.

Grit Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Grit Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 8, 2023
Series A ExtensionJul 15, 2021
Series ADec 1, 2020

Key People

Founding team and executive leadership

Jie J.

Chief Operating Officer

Executive Team

Grit Biotherapeutics Investors

Notable investors and investment history

Grit Biotherapeutics investors
InvestorRounds
Yuanhe CapitalSeries B
China International Capital CorporationSeries B
Liando InvestmentSeries B
MPCiSeries B, Series A, Series A Extension
Sherpa Healthcare PartnersSeries B, Series A
Decheng CapitalSeries B, Series A, Series A Extension
Apricot CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 8, 2023

    $60M round led by China International Capital Corporation.

  • Jul 15, 2021

    Raised Series A Extension with investors including Apricot Capital and Decheng Capital.

Grit Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Grit Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Grit Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range15
Year Founded2019
Last FundingSep 8, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.